Abstract
Compounds, pharmaceutical compositions and methods for treating viral and bacterial infections, by administering certain thiourea compounds, specifically acylthiourea, carboximidoylthiourea and S-alkyl isothiourea derivatives and analogs, in therapeutically effective amounts are disclosed.
Claims
-
A method for the treatment of a viral or bacterial infection or disease associated therewith wherein the viral infection is caused by a virus family selected from the group consisting of: Bunyaviridae, Poxviridae, Arenaviridae, Picornaviridae, Togaviridae, Flaviviridae, Filoviridae, Paramyxoviridae, Orthomyxoviridae and Retroviridae, comprising administering in a therapeutically effective amount to a mammal in need thereof, a compound of Formula II below or a pharmaceutically acceptable salt thereof:
wherein X is selected from the group consisting of oxygen and NH;
Y is selected from the group consisting of: —CH2—, —C(═O)—, —C(═S)— and —C(═NH)—;
A is selected from the group consisting of: N and CR5;
B is selected from the group consisting of: N and CR6;
R1 is selected from the group consisting of: hydrogen and ethyl;
R2 is selected from the group consisting of: hydrogen and chloro;
R3 is selected from the group consisting of: hydrogen, methoxy, amino and hydroxyl;
R4 is selected from the group consisting of: hydrogen, chloro and amino;
R5 is selected from the group consisting of hydrogen and aminomethyl; and
R6 is selected from the group consisting of hydrogen, amino and aminomethyl.
- The method of claim 1, wherein X is oxygen.
- The method of claim 1, wherein Y is —CH2—.
- The method of claim 1, wherein Y is —C(═O)—.
- The method of claim 1, wherein A is C—H.
- The method of claim 1, wherein B is C—H.
- The method of claim 1, wherein R1 is hydrogen.
- The method of claim 1, wherein R2 is hydrogen.
- The method of claim 1, wherein R3 is methoxy.
- The method of claim 1, wherein R4 is chloro.
- The method of claim 1, wherein each of R5 and R6 is hydrogen.
- The method of claim 1, wherein the compound of Formula II is selected from the group consisting of: N-[4-[(4-tert-butylbenzoyl)-carbamothioylamino]-2-hydroxy-phenyl]-2-chloro-benzamide; 4-tert-butyl-N-[[4-[(2-chlorophenyl)-methylamino]-3-methoxy-phenyl]-carbamothioyl]-benzamide; N-[2-amino-4-[(4-tert-butylbenzoyl)-carbamothioylamino]-phenyl]-2-chloro-benzamide hydrochloride; N-[(4-benzamido-2-chloro-phenyl)carbamothioyl]-4-tert-butyl-benzamide; 4-tert-butyl-N-[[4-[(2-chlorobenzene-carbothioyl)amino]-3-methoxy-phenyl]-carbamothioyl]benzamide; 4-(aminomethyl)-N-[4-[(4-tert-butylbenzoyl)-carbamothioylamino]-2-methoxy-phenyl]benzamide hydrochloride; N-[4-[(4-tert-butylbenzene-carboximidoyl) -carbamothioylamino]-2-methoxy-phenyl]-2-chloro-benzamide; 4-tert-butyl-N-[[4-[(2-chlorobenzene-carboximidoyl)amino]-3-methoxy-phenyl]-carbamothioyl]benzamide; 3-(aminomethyl)-N-[4-[(4-tert-butylbenzoyl)-carbamothioylamino]-2-methoxy-phenyl]benzamide hydrochloride; 2-amino-N-[4-[(4-tert-butylbenzoyl)-carbamothioylamino]-2-methoxy-phenyl]benzamide; N-[4-[(4-tert-butylbenzoyl)-carbamothioylamino]-2-methoxy-phenyl]pyridine-3-carboxamide; N-[4-[(4-tert-butylbenzoyl)-carbamothioylamino]-2-methoxy-phenyl]pyridine-4-carboxamide; N-[[4-[(4-aminobenzoyl)amino]-3-methoxy-phenyl]-carbamothioyl]-4-tert-butyl-benzamide hydrochloride; N-[4-[(4-tert-butylbenzoyl) -carbamothioyl-ethyl-amino]-2-methoxy-phenyl]-2-chloro-benzamide; N-[4-[(4-tert -butylbenzoyl)-carbamothioylamino]-2-methoxy-phenyl]-2-chloro-benzamide; and N-[(4-benzamidophenyl)-carbamothioyl]-4-tert-butyl-benzamide.
- The method of claim 12, wherein the compound of Formula II is N-[2-amino-4-[(4-tert-butylbenzoyl)-carbamothioylamino]-phenyl]-2-chloro-benzamide hydrochloride.
- The method of claim 1, wherein the mammal is a human.
- The method of claim 1, wherein said Bunyaviridae is selected from the group consisting of Rift Valley fever virus, La Crosse virus and Andes virus.
- The method of claim 1, wherein said Poxviridae is selected from the vaccinia virus and monkeypox virus.
- The method of claim 1, wherein said Arenaviridae is selected from the group consisting of Tacaribe virus and lymphocytic choriomeningitis virus.
- The method of claim 1, wherein said Picornaviridae is Encephalomyocarditis virus.
- The method of claim 1, wherein said Togaviridae is Sindbis virus.
- The method of claim 1, wherein said Flaviviridae is Dengue virus.
- The method of claim 1, wherein the viral infection is caused by a Filoviridae and said Filoviridae is Ebola virus.
- The method of claim 1, wherein said Orthomyxoviridae is an influenza virus.
- The method of claim 22, wherein said influenza virus is H1N1 virus.
- The method of claim 1, wherein said Retroviridae is a Human Immunodeficiency virus.
- The method of claim 1, which further comprises co-administration of at least one agent selected from the group consisting of antiviral agent, vaccine, and interferon.
- The method of claim 25, wherein said antiviral agent is Ribavirin.
- The method of claim 25, wherein said antiviral agent is cidofovir.
- The method of claim 25, wherein said interferon is pegylated.
- The method of claim 1, wherein said bacterial infection is caused by a bacteria family selected from the group consisting of Chlamydiaceae and Coxiellaceae.
- The method of claim 29, wherein said Chlamydiaceae is selected from the group consisting of Chlamydophila caviae and Chlamydophila muridarum.
- The method of claim 29, wherein said Coxiellaceae is Coxiella burnetti.
- The method of claim 1, wherein the compound of Formula II is N-[4-[(4-tert -butylbenzoyl)-carbamothioylamino]-2-methoxy-phenyl]-2-chloro-benzamide.
- The method of claim 32, wherein the viral infection is Ebola virus.
Owners (US)
-
Siga Technolgies Inc
(Aug 20 2012)
Explore more patents:
Applicants
-
Siga Tech Inc
Explore more patents:
Inventors
-
Allen Iii Robert D
Explore more patents:
-
Amberg Sean M
Explore more patents:
-
Dai Dongcheng
Explore more patents:
-
Burgeson James R
Explore more patents:
-
Hruby Dennis E
Explore more patents:
CPC Classifications
-
A61K31/17
Explore more patents:
-
A61K31/4406
Explore more patents:
-
A61K31/4409
Explore more patents:
-
A61K31/675
Explore more patents:
-
A61K31/7056
Explore more patents:
-
A61K38/21
Explore more patents:
-
A61K45/06
Explore more patents:
-
A61K47/60
Explore more patents:
-
C07C335/20
Explore more patents:
-
C07C335/26
Explore more patents:
-
C07C335/38
Explore more patents:
-
C07D213/81
Explore more patents:
-
C07D213/82
Explore more patents:
-
C07D495/04
Explore more patents:
-
Y02A50/385
Explore more patents:
-
Y02A50/397
Explore more patents:
-
Y02A50/463
Explore more patents:
-
Y10S514/888
Explore more patents:
IPC Classifications
-
A61K31/17
Explore more patents:
-
A61K31/4409
Explore more patents:
-
A61K31/675
Explore more patents:
-
A61K31/7056
Explore more patents:
-
A61K38/21
Explore more patents:
-
A61K45/06
Explore more patents:
-
C07C335/20
Explore more patents:
-
C07C335/26
Explore more patents:
-
C07C335/38
Explore more patents:
-
C07D213/81
Explore more patents:
-
C07D213/82
Explore more patents:
-
C07D495/04
Explore more patents:
Document Preview
- Publication: Feb 14, 2017
-
Application:
Dec 1, 2015
US 201514955697 A
-
Priority:
Dec 1, 2015
US 201514955697 A
-
Priority:
Sep 5, 2012
US 201213578413 A
-
Priority:
Feb 18, 2011
US 2011/0025356 W
-
Priority:
Feb 19, 2010
US 30610210 P